Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria
Venous thromboembolism is the most common cause of death in cancer patients with venous thrombosis. Treatment of venous thrombosis is important in cancer patients, as it can have a major impact on prognosis. We report a case of advanced gastric cancer that was discovered owing to pulmonary thromboem...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-09-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X19878047 |
| _version_ | 1818517776855203840 |
|---|---|
| author | Takuro Takama Mitsunori Fukue Koji Kanaya Masato Taniuchi |
| author_facet | Takuro Takama Mitsunori Fukue Koji Kanaya Masato Taniuchi |
| author_sort | Takuro Takama |
| collection | DOAJ |
| description | Venous thromboembolism is the most common cause of death in cancer patients with venous thrombosis. Treatment of venous thrombosis is important in cancer patients, as it can have a major impact on prognosis. We report a case of advanced gastric cancer that was discovered owing to pulmonary thromboembolism and describe the treatment for both conditions. Dose reduction criteria of edoxaban are established. Appropriate dose was based on body weight and creatinine clearance; patients with creatinine clearance values slightly exceeding or below 50 are considered to be on the borderline of the dose reduction criteria. This case had borderline value (body weight: 63 kg, creatinine clearance: 46 mL/min). We observed no response after initiating treatment with 30 mg edoxaban; however, pulmonary thrombus disappeared after increasing the dose to 60 mg edoxaban. When selecting an anticoagulation drug in borderline patients with cancer-associated thrombosis, dose increase should be considered if hemorrhage risk is assessed. |
| first_indexed | 2024-12-11T01:00:53Z |
| format | Article |
| id | doaj.art-8763717b19e04be3b304bfa58b8ea877 |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-12-11T01:00:53Z |
| publishDate | 2019-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-8763717b19e04be3b304bfa58b8ea8772022-12-22T01:26:19ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2019-09-01710.1177/2050313X19878047Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteriaTakuro Takama0Mitsunori Fukue1Koji Kanaya2Masato Taniuchi3Department of Cardiology, Yamachika Memorial Hospital, Odawara, JapanDepartment of Cardiology, Yamachika Memorial Hospital, Odawara, JapanDepartment of Surgery, Yamachika Memorial Hospital, Odawara, JapanDepartment of Cardiology, Yamachika Memorial Hospital, Odawara, JapanVenous thromboembolism is the most common cause of death in cancer patients with venous thrombosis. Treatment of venous thrombosis is important in cancer patients, as it can have a major impact on prognosis. We report a case of advanced gastric cancer that was discovered owing to pulmonary thromboembolism and describe the treatment for both conditions. Dose reduction criteria of edoxaban are established. Appropriate dose was based on body weight and creatinine clearance; patients with creatinine clearance values slightly exceeding or below 50 are considered to be on the borderline of the dose reduction criteria. This case had borderline value (body weight: 63 kg, creatinine clearance: 46 mL/min). We observed no response after initiating treatment with 30 mg edoxaban; however, pulmonary thrombus disappeared after increasing the dose to 60 mg edoxaban. When selecting an anticoagulation drug in borderline patients with cancer-associated thrombosis, dose increase should be considered if hemorrhage risk is assessed.https://doi.org/10.1177/2050313X19878047 |
| spellingShingle | Takuro Takama Mitsunori Fukue Koji Kanaya Masato Taniuchi Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria SAGE Open Medical Case Reports |
| title | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| title_full | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| title_fullStr | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| title_full_unstemmed | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| title_short | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| title_sort | treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| url | https://doi.org/10.1177/2050313X19878047 |
| work_keys_str_mv | AT takurotakama treatmentofpulmonarythromboembolismwithedoxabaninacancerpatientwithborderlinefulfillmentofthedosereductioncriteria AT mitsunorifukue treatmentofpulmonarythromboembolismwithedoxabaninacancerpatientwithborderlinefulfillmentofthedosereductioncriteria AT kojikanaya treatmentofpulmonarythromboembolismwithedoxabaninacancerpatientwithborderlinefulfillmentofthedosereductioncriteria AT masatotaniuchi treatmentofpulmonarythromboembolismwithedoxabaninacancerpatientwithborderlinefulfillmentofthedosereductioncriteria |